Subsequently, thanks to the IPOWER010 trial, the FDA approved pre-operative atezolizumab in resectable stage II to IIIA NSCLC with a PD-L1 expression of 1% or greater [15,16]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.